poisar

Stock

BioLife Solutions, Inc. BLFS

$35.07-0.45%

Overview

BLFS market data

Price History

BLFS price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
29.50
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.10
Diluted earnings per share over the trailing twelve months.
Beta
1.84
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
56.4%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$17.86 – $35.35
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $1.7B · P/B 3.13 · P/S 16.63.

Company News

10 captured
Benchmark Downgrades BioLife Solutions to HoldBenzinga · Aug 10, 2026, 1:40 PM
BioLife Solns Q2 Sales $28.466M Beat $27.683M EstimateBenzinga · Aug 6, 2026, 8:05 PM
8-K filing — BIOLIFE SOLUTIONS INC (BLFS)SEC EDGAR · Aug 3, 2026, 9:15 PM
Halper Sadeh LLC is Investigating Whether UTZ, BLFS, NRIM are Obtaining Fair Deals for their ShareholdersGlobenewswire Inc · Jul 30, 2026, 11:00 AM
Stephens & Co. Downgrades BioLife Solutions to Equal-Weight, Lowers Price Target to $31Benzinga · Jul 27, 2026, 5:24 PM
Jefferies Downgrades BioLife Solutions to Hold, Raises Price Target to $31Benzinga · Jul 23, 2026, 6:10 PM
TD Cowen Downgrades BioLife Solutions to Hold, Lowers Price Target to $31Benzinga · Jul 23, 2026, 5:17 PM
HC Wainwright & Co. Downgrades BioLife Solutions to Neutral, Lowers Price Target to $31Benzinga · Jul 23, 2026, 10:31 AM
Repligen Strengthens Cell Therapy Portfolio With BioLife AcquisitionBenzinga · Jul 22, 2026, 1:42 PM
BioLife Solutions To Be Acquired By Repligen For $31 Per Share In Cash And RGEN Stock At EV Of ~$1.5BBenzinga · Jul 22, 2026, 10:03 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock